Similarly, studies utilizing alternative surrogate markers for tumor progression other than PSA were not included, in accordance with the regulation of the German S3 guideline on Complementary Oncology [8] which also accepts only PSA and none of the other tumor markers due to its high acceptance as a marker in prevention, surveillance, and during treatment. This evidence concerns the gene KLK3 and neoplasm.